Hanson Wade have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.

Globally it’s estimated 1 in 7 people suffer from migraines. Migraines are one of the most disabling, misunderstood and underfunded diseases that costs the U.S. approximately $22 billion annually in direct and indirect costs to the economy.

The inaugural Migraine Drug Development Summit is the industry’s first dedicated discussion and networking forum focused on bringing together migraine thought-leaders to share the latest scientific progress and address the current challenges drug developers are facing.

Download the full event guide here to view the complete agenda and expert speaker line-up.

Developed with experts from Teva, Allergan, Eli Lilly and more, join over 60 of your peers at this intimate discussion led forum to:

  • Explore novel targets and mechanisms of action
  • Share lesson learned in mitigating the placebo response & the pathophysiology of migraine, whilst gaining an understanding of what this means for the future of migraine drug development
  • Leave with a deeper understanding of the current migraine landscape
  • Understand where key industry stakeholders are directing their next steps for migraine drug development.

“I was impressed by many of the speakers and learnt a significant amount, which I was able to bring back to our discovery team.” Stephen Krause, Senior Principal Scientist, Eisai

“Excellent networking and learning opportunity for pharma scientists.” Matthew Kennedy, Director, Merck

“The quality of talks was high and the discussion very interesting.” Claudio Babiloni, Associate Professor, University of Rome

Media Partner